Turbo-Power
Laser atherectomy catheter
Atherectomy devices
  • Philips Peripheral Laser Atherectomy Catheter Animation
  • Standard product photograph

Turbo-Power

Laser atherectomy catheter
Atherectomy devices
The Turbo-Power laser atherectomy catheter debulks the lesion in a single step and offers remote automatic rotation for precise directional control. Turbo-Power is the only atherectomy device proven and approved for the treat of ISR.

Clinical image gallery

  • Maximal luminal gain¹, ³⁻⁶
    Maximal luminal gain¹, ³⁻⁶
Features
Precise directional control
Remote automatic rotation offers precise directional control allowing the physician to direct treatment into bulk where needed.
Precise directional control
Clinical superiority
The only atherectomy device with level 1 clinical data. The Excite** ISR prospective randomized controlled trial, including challenging real-world cases with the longest lesions ever studied, proves superiority over PTA alone.¹
Clinical superiority
Fiber pack eccentric rotation
Increases crossing efficiency in calcified lesions allowing for better deliverability in difficult cases.¹⁰
Fiber pack eccentric rotation
Specifications
  • Model number 423-050
    Catheter diameter
    2.3 mm
    Vessel diameter
    ≥3.5 mm
    Max guidewire compatibility
    0.018"
    Sheath compatibility
    7F
    Max tip outer diameter
    0.091"
    Max shaft outer diameter
    0.091"
    Working length
    120 cm
    Fluence
    30-60 mJ / mm²
    Repetition rate
    25-80 Hz
  • Model number 420-050
    Vessel diameter
    ≥3.0 mm
    Catheter diameter
    2.0 mm
    Max guidewire compatibility
    0.018"
    Sheath compatibility
    6F
    Max tip outer diameter
    0.080"
    Max shaft outer diameter
    0.081"
    Working length
    150 cm
    Fluence
    30-60 mJ / mm²
    Repetition rate
    25-80 Hz

Documentation

Turbo-Power Brochure
PDF|4.22 MB

Related products

  • CVX-300 Excimer laser system
    CVX-300
    The only PMA approved excimer laser system and disposable catheters for the treatment of coronary arterial disease. CVX-300 is also indicated for use in the treatment of peripheral arterial disease. Photoablation is the use of light to break down, vaporize and remove matter. The CVX-300 excimer laser system facilitates photoablation via a variety of Philips laser catheters to remove binding arterial plaques.
  • Philips Laser System — Nexcimer Laser system for coronary and peripheral atherectomy and lead management
    Philips Laser System — Nexcimer
    Philips Laser System —Nexcimer— photoablates a wide spectrum of morphologies. Philips laser catheters are indicated in many vessel types and is the only laser system available for lead removal. Powered by a common 100-240V electrical outlet, the system warms up in less than 30 seconds for an easy and fast set-up.
  • Phoenix Atherectomy System Rotational atherectomy system
    Phoenix Atherectomy System
    The Phoenix atherectomy system combines the benefits of existing atherectomy systems to deliver a unique atherectomy option to help physicians tailor the treatment approach for each patient.¹ It cuts, captures, and clears diseased tissue with one insertion. Phoenix treats a broad range of tissue types, from soft plaque to calcified arteries, and can be used for lesions above and below the knee.²,³
Disclaimer
1. Dippel et al. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-stent Restenosis: Initial EXCITE ISR Results (2015). JACC 8(1): 92-101.
2. Saxon et al (2013). Heparin bonded, expanded polytetrafluoroethylene lined stent graft in the treatment of femoropopliteal artery disease. JVIR; 24(2).
3. McKinsey J, Zellar T, Rocha-Singh K, et al. Lower Extremity Revascularization Using Directional Atherectomy: 12-Moth Prospective Results of the DEFINITIVE LE Study, JACC Cardiovasc Interv 7 (2014) pp. 923-933.
4. Maehara A, et al. JETSTREAM Atherectomy System can remove superficial calcium in severely calcified peripheral arteries. Abstract Poster, ISET Jan 2013.
5. Babaev A, et al. Tissue Removal Assessment with Ultrasound of the SFA and Popliteal Study (TRUTH): Orbital Atherectomy Acute Date and Intravascular Ultrasound Analysis. JACC Vol 64/11/Suppl B, TCT-131.
6. Maximal luminal gain defined as 50% or greater stenosis reduction.
7. Spectranetics Benchmark Study, unpublished data available upon request. Coll Cardio. 2004;43:1959-1963.
8. Data on file D040242-00
9. Data on file ECO031891
*When comparing 7F Turbo-Power to 2.0 Turbo-Elite. Greater than 10% luminal gain when comparing 6F Turbo- Power to 2.0 Turbo-Elite.
**Excite ISR studied the safety and efficacy of Turbo-Tandem plus PTA and PTA alone. Turbo-Power is substantially equivalent to Turbo-Tandem.
Product availability is subject to country regulatory clearance. Please contact your local sales representative to check the availability in your country.